Hemab Therapeutics (NASDAQ:COAG) Shares Up 6% - Time to Buy?

Key Points

• Hemab Therapeutics shares rose 6% to about $30.43, giving the company a market capitalization of approximately $1.41 billion.
• Analyst sentiment is broadly positive: five analysts rate the stock a Buy, one rates it Hold, and one rates it Sell. The consensus rating is Moderate Buy, with a $51.40 price target.
• The company remains loss-making and missed quarterly EPS estimates, reporting a loss of $0.80 per share versus the expected $0.63 loss. Hemab is developing HMB-001, an investigational treatment for serious bleeding disorders.

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) shot up 6% on Thursday. The company traded as high as $30.65 and last traded at $30.43. 238,850 shares traded hands during trading, a decline of 36% from the average daily volume of 376,088 shares. The stock had previously closed at $28.70.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. HC Wainwright raised their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Wedbush boosted their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. Weiss Ratings downgraded Hemab Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, September 25th. Finally, Jefferies Financial Group boosted their price target on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.40.

Hemab Therapeutics Trading Up 5.4%

The business has a fifty day moving average of $43.34. The stock has a market capitalization of $1.41 billion and a PE ratio of -1.22.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17). As a group, equities research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Hemab Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth $230,000. The Manufacturers Life Insurance Company bought a new position in shares of Hemab Therapeutics during the 2nd quarter worth about $688,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $1,750,000. State Street Corp acquired a new stake in Hemab Therapeutics during the second quarter worth about $2,825,000. Finally, Braidwell LP acquired a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics NASDAQ: COAG is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab's lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.